CAPTRUST Financial Advisors
SLNO

CAPTRUST Financial Advisors’s Soleno Therapeutics SLNO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,058
Closed -$244K – 2592
2023
Q4 		$244K Sell
6,058
-4,128
-41% -$117K ﹤0.01% 2251
2023
Q3 		$301K Buy
+10,186
New +$61.7K ﹤0.01% 1995

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAPTRUST Financial Advisors's SLNO Position: Q1 2024 in Review

CAPTRUST Financial Advisors sold out of Soleno Therapeutics (SLNO) in Q1 2024, closing a stake of 6,058 shares — an estimated $244K sold.

CAPTRUST Financial Advisors first reported a position in SLNO in Q3 2023 and held it in 2 quarters. The position peaked at $301K in Q3 2023. 98 funds tracked by Wall St. Rank hold SLNO as of Q1 2024.

  • CAPTRUST Financial Advisors reported no remaining Soleno Therapeutics position as of Q1 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 6,058 Soleno Therapeutics shares in Q1 2024, an estimated $244K.
  • CAPTRUST Financial Advisors first reported a position in Soleno Therapeutics in Q3 2023 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Soleno Therapeutics position peaked at $301K in Q3 2023.
  • 98 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2024, filed 15 May 2024.